|
1
|
Lee C, Raffaghello L and Longo VD:
Starvation, detoxification, and multidrug resistance in cancer
therapy. Drug Resist Updat. 15:114–122. 2012. View Article : Google Scholar :
|
|
2
|
Street CA and Bryan BA: Rho kinase
proteins-pleiotropic modulators of cell survival and apoptosis.
Anticancer Res. 31:3645–3657. 2011.
|
|
3
|
Somlyo AP and Somlyo AV: Ca2+
sensitivity of smooth muscle and nonmuscle myosin II: Modulated by
G proteins, kinases, and myosin phosphatase. Physiol Rev.
83:1325–1358. 2003. View Article : Google Scholar
|
|
4
|
Zicha D, Dobbie IM, Holt MR, Monypenny J,
Soong DY, Gray C and Dunn GA: Rapid actin transport during cell
protrusion. Science. 300:142–145. 2003. View Article : Google Scholar
|
|
5
|
Brown M, Roulson JA, Hart CA, Tawadros T
and Clarke NW: Arachidonic acid induction of Rho-mediated
transendothelial migration in prostate cancer. Br J Cancer.
110:2099–2108. 2014. View Article : Google Scholar :
|
|
6
|
Ridley AJ: Rho proteins and cancer. Breast
Cancer Res Treat. 84:13–19. 2004. View Article : Google Scholar
|
|
7
|
Sahai E and Marshall CJ: RHO-GTPases and
cancer. Nat Rev Cancer. 2:133–142. 2002. View Article : Google Scholar
|
|
8
|
Burbelo P, Wellstein A and Pestell RG:
Altered Rho GTPase signaling pathways in breast cancer cells.
Breast Cancer Res Treat. 84:43–48. 2004. View Article : Google Scholar
|
|
9
|
Morgan-Fisher M, Wewer UM and Yoneda A:
Regulation of ROCK Activity in cancer. J Histochem Cytochem.
61:185–198. 2013. View Article : Google Scholar :
|
|
10
|
Amano M, Nakayama M and Kaibuchi K:
Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell
polarity. Cytoskeleton (Hoboken). 67:545–554. 2010. View Article : Google Scholar :
|
|
11
|
Yang X, Liu Y, Zong Z and Tian D: The Rho
kinase inhibitor fasudil inhibits the migratory behaviour of 95-D
lung carcinoma cells. Biomed Pharmacother. 64:58–62. 2010.
View Article : Google Scholar
|
|
12
|
Yang X, Di J, Zhang Y, Zhang S, Lu J, Liu
J and Shi W: The Rho-kinase inhibitor inhibits proliferation and
metastasis of small cell lung cancer. Biomed Pharmacother.
66:221–227. 2012. View Article : Google Scholar
|
|
13
|
Bass BL: Double-stranded RNA as a template
for gene silencing. Cell. 101:235–238. 2000. View Article : Google Scholar
|
|
14
|
Yang X, Zheng F, Zhang S and Lu J: Loss of
RhoA expression prevents proliferation and metastasis of SPCA1 lung
cancer cells in vitro. Biomed Pharmacother. 69:361–366. 2015.
View Article : Google Scholar
|
|
15
|
Shin JY, Kim JO, Lee SK, Chae HS and Kang
JH: LY294002 may overcome 5-FU resistance via down-regulation of
activated p-AKT in Epstein-Barr virus-positive gastric cancer
cells. BMC Cancer. 10:4252010. View Article : Google Scholar :
|
|
16
|
Chen T, Xu Y, Guo H, Liu Y, Hu P, Yang X,
Li X, Ge S, Velu SE, Nadkarni DH, et al: Experimental therapy of
ovarian cancer with synthetic makaluvamine analog: In vitro and in
vivo anticancer activity and molecular mechanisms of action. PLoS
One. 6:e207292011. View Article : Google Scholar :
|
|
17
|
Morgensztern D, Campo MJ, Dahlberg SE,
Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist
RS, Hensing T, et al: Molecularly targeted therapies in non-small
cell lung cancer annual update 2014. J Thorac Oncol. 10(1 Supp 1):
S1–S63. 2015. View Article : Google Scholar :
|
|
18
|
Pooja D, Panyaram S, Kulhari H, Reddy B,
Rachamalla SS and Sistla R: Natural polysaccharide functionalized
gold nanoparticles as biocompatible drug delivery carrier. Int J
Biol Macromol. 80:48–56. 2015. View Article : Google Scholar
|
|
19
|
Ying H, Biroc SL, Li WW, Alicke B, Xuan
JA, Pagila R, Ohashi Y, Okada T, Kamata Y and Dinter H: The Rho
kinase inhibitor fasudil inhibits tumor progression in human and
rat tumor models. Mol Cancer Ther. 5:2158–2164. 2006. View Article : Google Scholar
|
|
20
|
Rath N and Olson MF: Rho-associated
kinases in tumorigenesis: Re-considering ROCK inhibition for cancer
therapy. EMBO Rep. 13:900–908. 2012. View Article : Google Scholar :
|
|
21
|
Nakajima M, Hayashi K, Katayama K, Amano
Y, Egi Y, Uehata M, Goto N and Kondo T: Wf-536 prevents tumor
metastasis by inhibiting both tumor motility and angiogenic
actions. Eur J Pharmacol. 459:113–120. 2003. View Article : Google Scholar
|
|
22
|
Wagner A, Röhrs V, Kedzierski R, Fechner H
and Kurreck J: A novel method for the quantification of
adeno-associated virus vectors for RNA interference applications
using quantitative polymerase chain reaction and purified genomic
adeno-associated virus DNA as a standard. Hum Gene Ther Methods.
24:355–363. 2013. View Article : Google Scholar
|
|
23
|
Yu H and Jove R: The STATs of cancer-new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar
|
